哪里想瘦打哪里！FDA批准Kythera注射药品上市在即

你才双下巴，你家人都双下巴！所谓美的意欲人皆有之。如果说赘肉是每一个期望以外完美身材的“妹纸”或“汉纸”的大敌，那么一个不止人意表十足的双下巴算得是这些人的人间仇敌了。每一分钟，国外都有人为自己的一张大饼脸而感到烦恼，虽然以外一个肉感十足的双下巴撕回头是才行有肉感的，但是还是有很多人的强于使其无法承受一个双下巴之重。您可千万别笑，这甚至仍未转变成一个强大的旧金山市场。根据旧金山指甲外科手术基金会的追查研究者说明了，68%的白人对自己的双下巴透露了“心灰意冷”之情。而有鉴于此，最近Kythera旧金山公司向FDA提交了其专门从事打倒双下巴的按摩注射式用药ATX-101。这种用药完成了许多“胖纸”梦寐以求的新功能，哪里想瘦打哪里，算得是驻点瘦身。不必以为这种近乎天真的用药只是一个开玩笑，在FDA的总部的指甲和耳鼻喉科用药专员会的无记名投票中所，医学专家可是以17：0的超高高票一致赞许其证券交易所。或许是因为这些医学专家中所也有很多不堪双下巴之苦吧。FDA也将方案于明年的5月底13日之前对其作不止终于决定。如果一切顺利的话，Kythera旧金山公司方案于明年下半年将该电子产品证券交易所，统计分析社会大众预计这一用药的年销售额将超过3亿美元之多。随着按摩用药旧金山市场的日趋变小，Kythera旧金山公司算得是下了一步好棋。旧金山公司于去年以8400万美元的价格从其前合作伙伴后发主导权所收回了这种用药的全部选举权。而Kythera旧金山公司也期望便是为契机在按摩用药旧金山市场中所固守拔寨。就在上个月底，Kythera旧金山公司和Actelion旧金山公司达成价值2700万美元的合作协议，为基础一种失败过的抗瘙痒用药，而这种用药被认为有可能开发不止一种治疗脱发的用药。详细全名报道：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.